← Leaderboards

Robert C Griggs

University Of Rochester

Google Scholar ↗PubMed ↗ORCID ↗

$26,725,330

Attributed

$34,377,130

Total exposure

27

Grants

13

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $7.1M · FY2005–24

$10M$7.5M$5M$2.5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

Funding mix

By agency

NIH$38,038,808 · 28

By mechanism

U01$13,723,842 · 1

U54$12,001,677 · 3

R01$5,726,592 · 1

T32$5,714,299 · 1

R13$306,862 · 10

R21$239,250 · 1

Top collaborators

Most similar at University Of Rochester

Same institution · by research overlap

Rabi Tawil$9,728,744
Katherine Mary Dympna Bushby$6,672,392
James E Melvin$15,081,375
Qing Ke$107,789
Richard T Moxley$13,171,275

Others in their field

Top investigators on “Clinical Research”

David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
Sonia M Thomas · Research Triangle Institute$700,865,642
Jeffrey P Krischer · University Of South Florida$611,867,176
Barton F Haynes · Duke University$538,862,577

Research focus

Clinical ResearchClinical TrialsNervous System DisorderFundingHuman SubjectUnited States National Institutes Of HealthResearch PersonnelPhenotypeMolecularInternationalQuality Of LifeHuman Therapy EvaluationCollaborationsPathologic ProcessFoundationsScientistBaseMuscle StrengthPrednisoneClinical InvestigatorPreventionMuscular DystrophyPharmaceutical PreparationsNeuromuscular Diseases

Grant awards (80)

Experimental Therapeutics in Neurological Disease$34,076

T32 · FY2024 · NS · contact PI

Experimental Therapeutics in Neurological Disease$398,666

T32 · FY2023 · NS · contact PI

Experimental Therapeutics in Neurological Disease$389,507

T32 · FY2022 · NS · contact PI

Experimental Therapeutics in Neurological Disease$373,684

T32 · FY2021 · NS · contact PI

Experimental Therapeutics in Neurological Disease$363,826

T32 · FY2020 · NS · contact PI

FOR-DMD: Double-blind randomized trial to optimize steroid regimen in Duchenne MD$379,059

U01 · FY2019 · NS · contact PI

Experimental Therapeutics in Neurological Disease$104,010

T32 · FY2019 · NS · contact PI

Neurotherapeutics Symposium 2019 â accelerating the pace of translation in neurological emergencies by enhancing diverse workforce in neuroscience and promoting transdisciplinary team science$20,000

R13 · FY2019 · NS

FOR-DMD: Double-blind randomized trial to optimize steroid regimen in Duchenne MD$1,228,519

U01 · FY2018 · NS · contact PI

Experimental Therapeutics in Neurological Disease$69,236

T32 · FY2018 · NS · contact PI

FOR-DMD: Double-blind randomized trial to optimize steroid regimen in Duchenne MD$1,412,277

U01 · FY2017 · NS · contact PI

Experimental Therapeutics in Neurological Disease$270,147

T32 · FY2017 · NS · contact PI

Experimental Therapeutics in Neurological Disease$3,146

T32 · FY2017 · NS · contact PI

FOR-DMD: Double-blind randomized trial to optimize steroid regimen in Duchenne MD$1,946,015

U01 · FY2016 · NS · contact PI

Experimental Therapeutics in Neurological Disease$275,413

T32 · FY2016 · NS · contact PI

Experimental Therapeutics in Neurological Disease$265,749

T32 · FY2015 · NS · contact PI

Experimental Therapeutics in Neurological Disease$149,196

T32 · FY2014 · NS · contact PI

Economic Considerations in the Development of Therapies for Neuromuscular Disease$25,500

R13 · FY2014 · NS · contact PI

FOR-DMD:Double-blind randomized trial to optimize steroid regimen in Duchenne MD$1,811,776

U01 · FY2013 · NS · contact PI

Experimental Therapeutics in Neurological Disease$181,176

T32 · FY2013 · NS · contact PI

Novel Molecular Mechanisms of Neuromuscular Disease: Implications for Therapy$36,000

R13 · FY2013 · NS · contact PI

FOR-DMD:Double-blind randomized trial to optimize steroid regimen in Duchenne MD$1,500,000

U01 · FY2012 · NS · contact PI

Experimental Therapeutics in Neurological Disease$199,342

T32 · FY2012 · NS · contact PI

FOR-DMD:Double-blind randomized trial to optimize steroid regimen in Duchenne MD$1,500,000

U01 · FY2011 · NS · contact PI

Experimental Therapeutics in Neurological Disease$245,143

T32 · FY2011 · NS · contact PI

Translational Neuromuscular Research, Diverse Diseases, Convergent Themes$20,000

R13 · FY2011 · NS · contact PI

FOR-DMD:Double-blind randomized trial to optimize steroid regimen in Duchenne MD$3,946,196

U01 · FY2010 · NS · contact PI

Dichlorphenamide vs Acetazolamide for Periodic Paralysis$1,770,309

R01 · FY2010 · NS · contact PI

Nervous System Channelopathies: Pathogenesis and Treatment$1,162,497

U54 · FY2010 · NS · contact PI

Experimental Therapeutics in Neurological Disease$219,163

T32 · FY2010 · NS · contact PI

Treatment Strategies for Neuromuscular Diseases: The Challenge of Recruitment$44,924

R13 · FY2010 · NS · contact PI

Nervous System Channelopathies: Pathogenesis and Treatment$1,113,166

U54 · FY2009 · NS · contact PI

Dichlorphenamide vs Acetazolamide for Periodic Paralysis$1,000,660

R01 · FY2009 · NS · contact PI

Experimental Therapeutics in Neurological Disease$210,321

T32 · FY2009 · NS · contact PI

Fostering Pharma-Academic Partnerships in Neuromuscular Experimental Therapeutics$20,000

R13 · FY2009 · NS · contact PI

Nervous System Channelopathies: Pathogenesis & Treatment$1,115,907

U54 · FY2008 · NS · contact PI

Dichlorphenamide vs Acetazolamide for Periodic Paralysis$300,000

R01 · FY2008 · NS · contact PI

Experimental Therapeutics in Neurological Disease$259,889

T32 · FY2008 · NS · contact PI

Nervous System Channelopathies: Pathogenesis & Treatment$161,375

U54 · FY2008 · NS · contact PI

Experimental Therapeutics of Neuromuscular Disease$47,500

R13 · FY2008 · AR · contact PI

Dichlorphenamide vs Acetazolamide for Periodic Paralysis$1,208,300

R01 · FY2007 · NS · contact PI

Nervous System Channelopathies: Pathogenesis & Treatment$1,185,225

U54 · FY2007 · NS · contact PI

Experimental Therapeutics in Neurological Disease$257,790

T32 · FY2007 · NS · contact PI

Novel Designs and Outcome Measures for Bench to Bedside Research on NMD$29,396

R13 · FY2007 · NS · contact PI

Nervous System Channelopathies: Pathogenesis & Treatment$1,190,151

U54 · FY2006 · NS · contact PI

Experimental Therapeutics in Neurological Disease$266,447

T32 · FY2006 · NS · contact PI

Plan forTrial to find Optimum Steroid Regimen in Duchenne Muscular Dystrophy$217,778

R34 · FY2006 · NS · contact PI

Novel treatment for muscle disease: Fueling the pipeline and finding the product$28,000

R13 · FY2006 · NS · contact PI

Nervous System Channelopathies: Pathogenesis &Treatment$1,224,224

U54 · FY2005 · RR

NERVOUS SYSTEM CHANNELOPATHIES: PATHOGENESIS &TREATMENT$1,224,224

U54 · FY2005 · RR

Experimental Therapeutics in Neurological Disease$266,097

T32 · FY2005 · NS

Dichlorphenamide vs Acetazolamide for Periodic Paralysis$1,447,323

R01 · FY2004 · NS

NERVOUS SYSTEM CHANNELOPATHIES: PATHOGENESIS &TREATMENT$1,187,454

U54 · FY2004 · RR

Nervous System Channelopathies: Pathogenesis &Treatment$1,187,454

U54 · FY2004 · RR

EXPERIMENTAL THERAPEUTICS IN NEUROLOGICAL DISEASE$170,625

T32 · FY2004 · NS

Pathogenesis and treatment of the periodic paralyses$35,542

R13 · FY2004 · NS

Molecular Characterization of Late-Onset Distal Myopathy$474

M01 · FY2004 · RR

Nervous System Channelopathies: Pathogenesis &Treatment$1,250,000

U54 · FY2003 · RR

EXPERIMENTAL THERAPEUTICS IN NEUROLOGICAL DISEASE$241,313

T32 · FY2003 · NS

EXPERIMENTAL THERAPEUTICS IN NEUROLOGICAL DISEASE$68,876

T32 · FY2002 · NS

MOLECULAR CHARACTERIZATION OF LATE ONSET DISTAL MYOPATHY$0

M01 · FY2002 · RR

OPEN LABEL EXT STUDY OF E&S TRIAL OF OXANDROLONE IN RX OF DUCHENNE DY$0

M01 · FY2002 · RR

RD, PC PROS TRIAL OF EFFICACY &SAFETY OF OXANDRIN IN TX OF DMD ANCI$0

M01 · FY2002 · RR

DOUBLE-B, PLACEBO-C, STUDY OF THE EFFECTS OF PREDNISONE ON SKELETAL MUSCLE$0

M01 · FY2002 · RR

R,,DB,PC PROSP TRIAL OF EFFICACY &SAFETY OF OXANDRIN IN TX OF DUCHEN$0

M01 · FY2002 · RR

CLINICAL CHARACTER OF INDIVIDUALS W/ LIMB GIRDLE MD$0

M01 · FY2002 · RR

PLAN FOR TRIAL OF DICHLORPHENAMIDE IN PERIODIC PARALYSIS$239,250

R21 · FY2001 · NS

EXPERIMENTAL THERAPEUTICS IN NEUROLOGICAL DISEASE$227,548

T32 · FY2001 · NS

COURSE OF DISEASE PROGRESSION IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS$19,613

M01 · FY2001 · RR

DOUBLE-B, PLACEBO-C, STUDY OF THE EFFECTS OF PREDNISONE ON SKELETAL MUSCLE$19,613

M01 · FY2001 · RR

THERAPEUTIC TRIAL OF PREDNISONE IN DUCHENE DYSTROPHY$19,613

M01 · FY2001 · RR

EFFECTS OF PREDNISONE ON SKELETAL MUSCLE$19,613

M01 · FY2001 · RR

EXPERIMENTAL THERAPEUTICS IN NEUROLOGICAL DISEASE$203,913

T32 · FY2000 · NS

DOUBLE-B, PLACEBO-C, STUDY OF THE EFFECTS OF PREDNISONE ON SKELETAL MUSCLE$14,791

M01 · FY2000 · RR

THERAPEUTIC TRIAL OF PREDNISONE IN DUCHENE DYSTROPHY$14,791

M01 · FY2000 · RR

MOLECULAR CHARACTERIZATION OF LATE ONSET DISTAL MYOPATHY$0

M01 · FY2000 · RR

OPEN LABEL EXT STUDY OF E&S TRIAL OF OXANDROLONE IN RX OF DUCHENNE DY$0

M01 · FY2000 · RR

RD, PC PROS TRIAL OF EFFICACY &SAFETY OF OXANDRIN IN TX OF DMD ANCI$0

M01 · FY2000 · RR

R,,DB,PC PROSP TRIAL OF EFFICACY &SAFETY OF OXANDRIN IN TX OF DUCHEN$0

M01 · FY2000 · RR

CLINICAL CHARACTER OF INDIVIDUALS W/ LIMB GIRDLE MD$0

M01 · FY2000 · RR